Kezic A, Becker J U, Thaiss F
School of Medicine, University of Belgrade, Serbia; Clinic of Nephrology, Clinical Center of Serbia, Belgrade, Serbia.
Transplant Proc. 2013 Jun;45(5):1708-14. doi: 10.1016/j.transproceed.2013.02.110.
Kidney ischemia-reperfusion injury (IRI) is associated with a robust inflammatory response, which is regulated by nuclear factor-kappaB (NF-κB), mainly its heterodimeric form p65/p50. Considering immunomodulatory properties of mammalian target of rapamycin (mTOR) inhibitors, the effect of everolimus on NF-κB activation in kidney IRI was determined in this study. IRI was induced in C57/BL6 mice by clamping both renal pedicles for 45 minutes. Application of everolimus (0.25 mg/kg bw subcutaneously daily) was started one day before IRI induction. Both everolimus-treated and nontreated mice were sacrificed at several times starting at 30 minutes and finishing on day 7 after IRI induction. The NF-κB activity, proinflammatory cytokines IL-1β, TNF-α, and anti-inflammatory cytokine IL-10 production were determined in kidneys. Compared with nontreated animals, everolimus-treated animals showed significantly increased TNF-α (2741.6 ± 201.72 pg/mg; 1925 ± 185.81 pg/mg, P < .05) and IL-1β (11.47 ± 1.2 pg/mg; 4.3 ± 0.13 pg/mg, P < .01) production on day 2 after IRI induction accompanied by significantly greater NF-κB/DNA binding activity and p65 nuclear expression (P < .01). Two hours after IRI induction, everolimus-treated animals showed significantly increased IL-1β mRNA expression (P < .05) followed by increased IL-1β protein concentrations when compared with nontreated animals measured 6 hours after IRI induction (11.71 ± 1.5 pg/mg; 7.5 ± 1.11 pg/mg, P < .01). Both experimental groups showed increased NF-κB/DNA binding activity at 7 days after IRI induction. Significantly increased nuclear p65 expression was measured in nontreated animals (P < .01), whereas everolimus-treated hosts showed significantly increased nuclear RelB expression (P < .01). These data suggested that everolimus potentiated innate immunity in the early phase of IRI, stimulating the production of NF-κB-driven proinflammatory cytokines such as TNF-α and IL-1β. The NF-κB activity was potentiated under m-TOR inhibition during kidney IRI, implicating a possible beneficial role of alternative NF-κB activation during the repair phase.
肾缺血再灌注损伤(IRI)与强烈的炎症反应相关,该炎症反应由核因子-κB(NF-κB)调控,主要是其异源二聚体形式p65/p50。考虑到雷帕霉素哺乳动物靶点(mTOR)抑制剂的免疫调节特性,本研究确定了依维莫司对肾IRI中NF-κB激活的影响。通过夹闭双侧肾蒂45分钟在C57/BL6小鼠中诱导IRI。在诱导IRI前一天开始皮下每日应用依维莫司(0.25mg/kg体重)。在诱导IRI后30分钟开始,在第7天结束,多次处死经依维莫司治疗和未治疗的小鼠。测定肾脏中的NF-κB活性、促炎细胞因子IL-1β、TNF-α和抗炎细胞因子IL-10的产生。与未治疗的动物相比,经依维莫司治疗的动物在IRI诱导后第2天显示TNF-α(2741.6±201.72pg/mg;1925±185.81pg/mg,P<.05)和IL-1β(11.47±1.2pg/mg;4.3±0.13pg/mg,P<.01)的产生显著增加,同时伴有显著更高的NF-κB/DNA结合活性和p65核表达(P<.01)。在IRI诱导后2小时,与未治疗的动物相比,经依维莫司治疗的动物显示IL-1βmRNA表达显著增加(P<.05),随后在IRI诱导后6小时测量时IL-1β蛋白浓度增加(11.71±1.5pg/mg;7.5±1.11pg/mg,P<.01)。两个实验组在IRI诱导后7天均显示NF-κB/DNA结合活性增加。在未治疗的动物中测量到核p65表达显著增加(P<.01),而经依维莫司治疗的宿主显示核RelB表达显著增加(P<.01)。这些数据表明,依维莫司在IRI的早期增强了先天免疫,刺激了NF-κB驱动的促炎细胞因子如TNF-α和IL-1β的产生。在肾IRI期间,m-TOR抑制下NF-κB活性增强,这意味着在修复阶段替代NF-κB激活可能具有有益作用。